- The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
- No new safety or tolerability findings in connection with tirasemtiv were identified in the study, the company said.
Nov 21 (Reuters) - Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.
The drug, tirasemtiv, was not statistically significant in slowing vital capacity, or the volume of air expelled from the lungs without force, in patients with amyotrophic lateral sclerosis, when compared with a placebo.
No comments:
Post a Comment